Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The growth hormone secretagogue receptor (GHSR1a), the target of the ghrelin peptide, is widely distributed throughout the brain, and, while studies have often reported very low or absent levels of central ghrelin, it is now known that GHSR1a, even in the absence of a natural ligand, has physiological roles. Not only do these roles originate from the receptor’s constitutive activity, but recent data indicate that GHSR1a dimerizes with a wide array of other receptors. These include the dopamine 1 receptor (D1R), the dopamine 2 receptor (D2R), the melanocortin-3 receptor (MC3R), the serotonin 2C receptor (5-HT 2C), and possibly the cannabinoid type 1 receptor (CB1). Within these dimers, signaling of the protomers involved are modified through facilitation, inhibition, and even modification of signaling pathways resulting in physiological consequences not seen in the absence of these dimers. While in some cases the ghrelin peptide is not required for these modifications to occur, in others, the presence is necessary for these changes to take effect. These heterodimers demonstrate the broad array of roles and complexity of the ghrelin system. By better understanding how these dimers work, it is hoped that improved treatments for a variety of disorders, including Parkinson’s disease, schizophrenia, addiction, obesity, diabetes, and more, can be devised. In this review, we examine the current state of knowledge surrounding GHSR heterodimers, and how we can apply this knowledge to various pharmacological treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide atlas of gene expression in the adult mouse brain
Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F., Boguski, M. S., Brockway, K. S., Byrnes, E. J., et al. (2007) · Nature · doi:10.1038/nature05453 · Cited by 5,572
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Cowley, M. A., Smith, R. G., Diano, S., Tschöp, M., Pronchuk, N., Grove, K. L., Strasburger, C. J., Bidlingmaier, M., Esterman, M., Heiman, M. L., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00063-1 · Cited by 1,679
Modulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · cited 1×
“…et al., 2003), prefrontal cortex and hippocampus (cognition, learning, and memory) (Sawaguchi et al., 1990; Sawaguchi and Goldman-Rakic, 1994; Williams and Goldman-Rakic, 1995; Otmakhova and Lisman, 1996; Matthies et al., 1997; Seamans et al., 1998; Granado et al., 2008), nucleus accumbens…”
BackgroundEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 2×
“While one would suspect that coadministration of rimonabant, a selective CB1 antagonist, with a GHSR1a antagonist or inverse agonist may help to decrease appetite, or may reduce body weight with less side effects due to reduced dosage (RinaldiCarmona et al., 1994; Després et al., 2005), our current understanding of th…”
BackgroundExpression of ghrelin receptor mRNA in the rat and the mouse brain
Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., & Elmquist, J. K. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20823 · Cited by 1,074 · cited 5×
“, 2010); and some of the overlapping expression profiles of 5-HT2C and GHSR1a (Abramowski et al., 1995; Guan et al., 1997; Cowley et al., 2003; Zigman et al., 2006).”
BackgroundInfluentialAbizaid, A., Liu, Z.-W., Andrews, Z. B., Shanabrough, M., Borok, E., Elsworth, J. D., Roth, R. H., Sleeman, M. W., Picciotto, M. R., Tschöp, M. H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29867 · Cited by 984 · cited 2×
“…mechanisms, its presence in extra hypothalamic regions, including a number of limbic and midbrain structures like the ventral tegmental area (VTA), suggest that this receptor is associated in processes associated with learning and motivation (Abizaid et al., 2006; Abizaid and Horvath, 2008).”
BackgroundSelf-citationBanks, W. A., Tschöp, M., Robinson, S. M., & Heiman, M. L. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034827 · Cited by 691 · cited 1×
“Nevertheless, the entry of peripheral ghrelin into the brain is limited and potentially binds only to areas of the brain that are less protected by the blood brain barrier like the arcuate and the area postrema in the brain stem (Banks et al., 2002; Cabral et al., 2013).”
BackgroundThe orexigenic hormone ghrelin defends against depressive symptoms of chronic stress
Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S. A., Anderson, J. G., Jung, S., Birnbaum, S., Yanagisawa, M., Elmquist, J. K., Nestler, E. J., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2139 · Cited by 644
Sinha, R., Garcia, M., Paliwal, P., Kreek, M. J., & Rounsaville, B. J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.324 · Cited by 528 · cited 1×
“Enhanced D1 receptor signaling would also explain why addicts are more prone to relapse when stressed or hungry, both conditions that augment ghrelin secretion and sensitivity (Carroll, 1985; Brown et al., 1995; Shalev et al., 2000; Shalev et al., 2001; Goeders, 2003; Sinha et al., 2006).”
Background
Cited by
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
A ghrelin receptor and oxytocin receptor heterocomplex impairs oxytocin mediated signalling
Wallace Fitzsimons, S. E., Chruścicka, B., Druelle, C., Stamou, P., Nally, K., Dinan, T. G., Cryan, J. F., & Schellekens, H. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.12.022 · Cited by 49
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39
Borroto-Escuela, D. O., Cuesta-Marti, C., Lopez-Salas, A., Chruścicka-Smaga, B., Crespo-Ramírez, M., Tesoro-Cruz, E., Palacios-Lagunas, D. A., Perez de la Mora, M., Schellekens, H., & Fuxe, K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1055344 · Cited by 38
“Sibling” battle or harmony: Crosstalk between nesfatin-1 and ghrelin
Chen, X., Dong, J., Jiao, Q., Du, X., Bi, M., & Jiang, H. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04193-6 · Cited by 17
Metadata
- Authors
- Wellman, M., & Abizaid, A.
- Venue
- eneuro
- Publisher
- Society for Neuroscience
- Published
- 2015-03
- Volume
- 2
- Issue
- 2
- Pages
- ENEURO.0053-14.2015
- ISSN
- 2373-2822 (ISSN-L)
- OpenAlex
- W2137519330
- Cited by
- 86
- References
- 17
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target. https://app.cochat.ai/papers/10.1523/eneuro.0053-14.2015
- The paper
- Wellman, M., & Abizaid, A. (2015). Growth Hormone Secretagogue Receptor Dimers: A New Pharmacological Target. eneuro. https://doi.org/10.1523/eneuro.0053-14.2015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.